News coverage about Cytori Therapeutics (NASDAQ:CYTX) has trended somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytori Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.7625290640579 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Roche Diagnostics terminates enzyme supply agreement with Cytori Therapeutics (seekingalpha.com)
- Analysts Anticipate Cytori Therapeutics (CYTX) Will Announce Earnings of -$0.50 Per Share (americanbankingnews.com)
- Cytori Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering (globenewswire.com)
- Cytori Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering (finance.yahoo.com)
A number of equities analysts recently issued reports on the company. ValuEngine raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Zacks Investment Research lowered Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 15th. HC Wainwright set a $40.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a report on Monday, May 14th. Maxim Group set a $20.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a report on Friday, May 11th. Finally, B. Riley raised Cytori Therapeutics from a “neutral” rating to a “buy” rating in a report on Friday, March 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.25.
Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.30). Cytori Therapeutics had a negative net margin of 428.14% and a negative return on equity of 190.35%. The business had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $2.43 million. During the same period in the prior year, the firm posted ($2.40) EPS. equities analysts predict that Cytori Therapeutics will post -1.74 EPS for the current fiscal year.
About Cytori Therapeutics
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.